SELECTIVE INHIBITORS OF HISTONE DEACETYLASE

(19)

(11)

EP 2 265 590 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	27.07.2016 Bulletin 2016/30

(45)	Mention of the grant of the patent:
	13.04.2016 Bulletin 2016/15

(21)	Application number: 09733489.0

(22)	Date of filing: 15.04.2009

(51)

International Patent Classification (IPC):

C07D 235/06^(2006.01)
C07D 235/10^(2006.01)
C07D 235/14^(2006.01)

C07D 235/08^(2006.01)
C07D 235/12^(2006.01)

(86)	International application number:
	PCT/US2009/040709

(87)	International publication number:
	WO 2009/129335 (22.10.2009 Gazette 2009/43)

(54)	SELECTIVE INHIBITORS OF HISTONE DEACETYLASE SELEKTIVE HISTONDEACETYLASE-HEMMER INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

15.04.2008 US 45198

(43)	Date of publication of application:
	29.12.2010 Bulletin 2010/52

(73)	Proprietor: Pharmacyclics LLC
	Sunnyvale, CA 94085 (US)

(72)	Inventors:
	VERNER, Erik Belmont CA 94002 (US) BALASUBRAMANIAN, Sriram San Carlos CA 94070 (US) BUGGY, Joseph, J. Mountain View CA 94040 (US)

(74)	Representative: Cole, William Gwyn et al
	Avidity IP Broers Building Hauser Forum 21 J J Thomson Ave Cambridge CB3 0FA Cambridge CB3 0FA (GB)

(56)

References cited: :

WO-A1-2005/028447
US-A1- 2005 137 234

WO-A2-2007/109178
US-A1- 2007 281 934

MAI ET AL: "3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydr oxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 1, 21 January 2004 (2004-01-21), pages 1098-1109, XP002292253, ISSN: 0022-2623, DOI: 10.1021/jm030990+
DAI YUJIA ET AL.: 'Inorganic amide hydroxamic acids as potent inhibitors of histone deacetylases' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 13, 2003, pages 1897 - 1901, XP002331281
LEE S. ET AL.: 'Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors' BIOORG MED CHEM LETT. vol. 17, no. 17, 01 September 2007, pages 4895 - 4900, XP022184931

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).